The thyroid gland is a master regulator of metabolism, and the gastrointestinal tract is one of its primary targets. Every cell in the gut wall has thyroid hormone receptors. When thyroid hormone levels drop, gut motility slows, gastric acid production decreases, and the migrating motor complex loses its rhythm. These are precisely the conditions that allow bacteria to overgrow in the small intestine. The connection between hypothyroidism and SIBO is well-documented but frequently overlooked in clinical practice. Many patients cycle through rounds of SIBO treatment without anyone checking their thyroid, and many hypothyroid patients struggle with GI symptoms that are attributed to their thyroid medication dosing rather than to bacterial overgrowth that developed as a consequence of their condition.
How thyroid hormones control gut motility
Thyroid hormones, primarily triiodothyronine (T3), regulate the speed and coordination of muscle contractions throughout the GI tract. T3 acts on smooth muscle cells in the intestinal wall to increase their contractile force and frequency. It also modulates the enteric nervous system, the network of neurons embedded in the gut wall that coordinates peristalsis independently of the brain. Additionally, thyroid hormones influence the interstitial cells of Cajal (ICC), the pacemaker cells that generate the electrical slow waves driving rhythmic gut contractions. When T3 levels are low, smooth muscle contractions weaken, the enteric nervous system becomes sluggish, and ICC signaling slows. The result is decreased peristalsis throughout the GI tract, with the stomach and small intestine particularly affected.
The constipation pattern and MMC disruption
Constipation is one of the most recognized symptoms of hypothyroidism. Studies show that orocecal transit time increases by 50-100% in hypothyroid patients compared to people with normal thyroid function. But constipation is only the visible symptom. Behind it, the migrating motor complex (MMC) is also impaired. The MMC is the sweeping wave that clears the small intestine of residual food particles and bacteria during fasting. It cycles approximately every 90-120 minutes in healthy individuals. In hypothyroid patients, MMC frequency and amplitude are both reduced, meaning the small intestine is not being cleaned between meals. This allows bacteria that would normally be swept into the colon to remain and multiply in the small intestine.
SIBO prevalence in hypothyroid patients
Lauritano et al. (2007) published one of the landmark studies on this topic, finding SIBO in 54% of patients with overt hypothyroidism using glucose breath testing. This is dramatically higher than the estimated SIBO prevalence of 2-20% in the general population. The study also demonstrated that treating SIBO improved GI symptoms in these patients independently of thyroid hormone optimization. Subsequent research has confirmed the association, with multiple studies showing elevated SIBO rates in both overt and subclinical hypothyroidism. The combination of slowed motility, reduced gastric acid output (hypochlorhydria is common in hypothyroidism), and impaired MMC function creates a multi-layered vulnerability to bacterial overgrowth.
âšī¸If you have been diagnosed with hypothyroidism and experience bloating, gas, diarrhea, or worsening constipation despite adequate thyroid hormone replacement, SIBO testing should be considered. These symptoms are often attributed to the thyroid condition itself but may reflect a treatable bacterial overgrowth.
The Hashimoto's autoimmune connection
Hashimoto's thyroiditis is the most common cause of hypothyroidism in the developed world, accounting for approximately 90% of cases. It is an autoimmune condition in which the immune system attacks thyroid tissue, gradually destroying the gland's ability to produce hormones. The autoimmune component adds an additional dimension to the thyroid-SIBO relationship. Autoimmune conditions tend to cluster, and Hashimoto's patients have higher rates of celiac disease, type 1 diabetes, autoimmune gastritis, and pernicious anemia, all of which independently affect gut function and SIBO risk. The systemic immune dysregulation present in Hashimoto's may also directly affect intestinal immune defenses, including secretory IgA production, which plays a key role in keeping bacterial populations in check.
The bidirectional cycle: how SIBO worsens thyroid function
The thyroid-SIBO relationship runs in both directions. SIBO can worsen thyroid function through several mechanisms. First, bacterial overgrowth in the small intestine impairs the absorption of levothyroxine, the standard thyroid hormone replacement medication. Centanni et al. (2006) demonstrated that SIBO patients required higher levothyroxine doses to achieve the same TSH levels as patients without SIBO, and that eradicating the overgrowth allowed dose reduction. Second, SIBO-related intestinal inflammation may impair the conversion of T4 (the inactive form) to T3 (the active form) that occurs in the gut. Third, the systemic inflammatory response triggered by bacterial overgrowth can suppress thyroid function centrally through effects on the hypothalamic-pituitary-thyroid axis. This creates a self-reinforcing cycle: hypothyroidism promotes SIBO, and SIBO worsens hypothyroidism.
Subclinical hypothyroidism and SIBO risk
Subclinical hypothyroidism is defined as an elevated TSH with normal free T3 and free T4 levels. It affects 4-10% of the general population and is particularly common in women over 60. The question of whether subclinical hypothyroidism carries SIBO risk is clinically important because many physicians consider it a mild condition that does not require treatment. However, emerging evidence suggests that even mildly elevated TSH levels are associated with decreased gut transit time. Patients with subclinical hypothyroidism report constipation, bloating, and GI discomfort at rates higher than euthyroid controls. Whether this translates to measurably increased SIBO rates is still under investigation, but the physiological rationale is sound: any reduction in thyroid hormone activity in the gut wall will slow motility to some degree.
Breaking the thyroid-SIBO cycle
Addressing the thyroid-SIBO connection requires treating both conditions simultaneously. Optimizing thyroid hormone levels restores motility and MMC function, reducing the conditions that allow bacterial overgrowth. Eradicating SIBO improves levothyroxine absorption and removes the inflammatory burden that may be suppressing thyroid function. Prokinetic agents can provide additional motility support during the transition period. For Hashimoto's patients, addressing intestinal permeability and immune dysregulation may also reduce the autoimmune burden contributing to both conditions. The key insight is that treating SIBO without addressing thyroid function, or optimizing thyroid hormones without checking for SIBO, leaves half the problem unsolved.
â ī¸This article is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition.